Pregnancy Registries: What We’re Learning About Medication Safety

Imagine you are eight weeks pregnant. You have been taking a specific medication for your autoimmune condition since before you knew you were expecting. Your doctor says it is likely safe, but they also admit there is no definitive proof. This uncertainty is the reality for millions of women every year. In the United States alone, about six million pregnancies occur annually, and roughly 80% of pregnant women take at least one prescription or over-the-counter drug during that time.

For decades, we relied on animal studies and small clinical trials to guess how these drugs might affect a developing fetus. But animals do not always react like humans, and ethical rules prevent us from testing new drugs directly on pregnant women in controlled trials. So, where does the real-world data come from? The answer lies in Pregnancy Registries, which are prospective observational studies designed to track the outcomes of pregnancies exposed to specific medications. These registries are our best tool for understanding medication safety after a drug hits the market.

What Exactly Is a Pregnancy Registry?

A pregnancy registry is not just a database; it is an active research study. Unlike passive systems where doctors report side effects only when something goes wrong, a registry actively recruits women who have taken a specific drug during pregnancy. They follow these women from the moment of exposure through delivery and often for months or even years afterward.

The primary goal, as defined by the Society for Birth Defects Research and Prevention, is to determine as early as possible whether a drug poses a teratogenic risk-meaning, can it cause birth defects? To do this, registries collect detailed information:

• Exposure Details: Which drug was taken, what dose, and at what stage of pregnancy (first trimester is critical for organ formation).
• Maternal Health: Information about the mother’s underlying condition, age, weight, and other health factors.
• Lifestyle Factors: Data on smoking, alcohol use, and other environmental exposures.
• Outcomes: Whether the pregnancy resulted in a live birth, miscarriage, preterm delivery, or specific congenital anomalies.

For example, the National Pregnancy Registry for Psychiatric Medications, operated by Massachusetts General Hospital, has been tracking outcomes for women taking antidepressants and antipsychotics for years. They recently expanded their scope to include 18 additional medications, bringing their total studied compounds to 45. This level of detail helps researchers separate the effects of the drug from the effects of the illness itself.

Why Can’t We Just Use Clinical Trials?

You might wonder why we don’t just run standard clinical trials on pregnant women. The short answer is ethics. Historically, pregnant women were excluded from most drug trials to protect the fetus from unknown risks. This created a massive gap in knowledge. By the time a drug is approved, we know how it works in healthy adults, but very little about its impact on a developing baby.

Pregnancy registries fill this post-marketing surveillance gap. They operate under the framework established by regulations like the FDA’s Pregnancy and Lactation Labeling Rule (PLLR), implemented in 2015. The PLLR replaced the old letter categories (A, B, C, D, X) with narrative descriptions, requiring manufacturers to provide more nuanced data on pregnancy and lactation safety. For many high-risk drugs, especially biologics, regulatory agencies like the FDA and the European Medicines Agency (EMA) now require companies to fund and maintain these registries as a condition of approval.

What Are We Learning? Key Insights from Recent Data

Over the past few years, pregnancy registries have provided crucial reassurance for many commonly used medications. Here is what the data is telling us:

Psychiatric Medications: One of the biggest fears for pregnant women with depression or bipolar disorder is that stopping medication will harm the baby, or that continuing it will cause defects. Dr. Martha Werler, Director of the National Pregnancy Registry for Psychiatric Medications, notes that current data shows most antidepressants do not significantly increase the risk of major birth defects. However, the registry data also highlights the importance of treating maternal mental health, as untreated depression carries its own risks for preterm birth and low birth weight.

Biologics for Autoimmune Diseases: With the rise of biologic therapies for conditions like rheumatoid arthritis and psoriasis, registries have become essential. Data from multiple registries suggests that many TNF inhibitors are safe to use throughout pregnancy. This has changed clinical practice, allowing women to stay on effective treatments rather than facing dangerous disease flares during gestation.

Antiepileptic Drugs: Registries have long tracked these medications because some older anticonvulsants are known teratogens. The data has helped clinicians switch patients to safer alternatives like lamotrigine or levetiracetam, reducing the incidence of neural tube defects and cleft lip/palate in this population.

The Limitations: Why Registries Aren’t Perfect

While invaluable, pregnancy registries have significant limitations that both doctors and patients need to understand. The biggest issue is sample size. As noted by experts like Dr. Allen Mitchell of Boston University, registries rarely enroll enough women to detect small increases in risk. For instance, if a birth defect occurs in 1 out of 1,000 pregnancies naturally, detecting a doubling of that risk would require thousands of exposed pregnancies. Most registries only capture dozens or hundreds.

This means a registry can tell you if a drug is likely safe (no signal detected), but it cannot definitively prove it is 100% safe. It also struggles with selection bias. Women who volunteer for registries might be different from those who don’t-they might be more health-conscious or have access to better care. Additionally, retention is hard. Dropout rates average 20-30%, meaning some outcome data is missing.

Dr. Sonia Hernandez-Diaz of Harvard T.H. Chan School of Public Health advocates for a "tiered approach." Registries should be used for initial signal detection, but larger database studies using electronic health records should be used to quantify the actual risk levels. Relying solely on registry data can give a false sense of precision.

How Do Women Participate?

If you are prescribed a medication that has an associated registry, your healthcare provider may invite you to join. Participation is entirely voluntary. Organizations like MotherToBaby often manage these registries, providing a neutral interface between pharmaceutical companies and patients. According to their 2022 annual report, 78% of participating women felt satisfied with the process, appreciating the personalized information they received.

However, recruitment remains a challenge. Only 15-20% of eligible women typically enroll. Barriers include concerns about privacy, the time commitment required for follow-up calls, and anxiety about contributing to data that won’t help them immediately. It is important to remember that joining a registry does not provide immediate medical advice for your individual case; it contributes to long-term scientific knowledge.

The Future of Medication Safety Monitoring

The landscape is evolving. The FDA launched the Pregnancy Safety Research Network in 2022 to coordinate efforts and standardize data collection across different registries. The goal is to integrate registry data with large-scale electronic health record databases. This hybrid approach aims to combine the high-quality exposure data of registries with the statistical power of big data.

We are also seeing a shift in regulatory requirements. With 65% of new biologics approved between 2018 and 2022 including pregnancy registry commitments, the infrastructure for monitoring is growing. The global market for pregnancy safety monitoring is projected to grow at 7.2% annually through 2030, reflecting the increasing complexity of modern pharmacotherapies.

For patients, this means more data will be available in the coming years. But for now, the decision to take medication during pregnancy remains a shared decision between you and your doctor, weighing the known risks of the disease against the potential, often unquantified, risks of the treatment. Pregnancy registries are the bridge that helps us cross from uncertainty to evidence-based confidence.